157 related articles for article (PubMed ID: 29289629)
1. Thrombosis of a Left Atrial Appendage Occluder After Treatment With Thrombopoietin Receptor Agonists.
Cubero-Gallego H; Romaguera R; Teruel L; Gomez-Lara J; Berdejo J; Gomez-Hospital JA; Cequier A
JACC Cardiovasc Interv; 2018 Jan; 11(2):e15-e16. PubMed ID: 29289629
[No Abstract] [Full Text] [Related]
2. Sustaining platelet counts in chronic ITP.
Nurden AT
Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
[No Abstract] [Full Text] [Related]
3. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
Kowalczyk M; Rubinstein PG; Aboulafia DM
J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
[TBL] [Abstract][Full Text] [Related]
4. Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis.
Polverelli N; Catani L; Sollazzo D; Vianelli N; Palandri F
Ann Hematol; 2015 Feb; 94(2):339-41. PubMed ID: 24994539
[No Abstract] [Full Text] [Related]
5. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
6. Transcatheter occlusion of left atrial appendage with persistent thrombus using a trans-radial embolic protection device.
Cammalleri V; Ussia GP; Muscoli S; De Vico P; Romeo F
J Cardiovasc Med (Hagerstown); 2016 Dec; 17 Suppl 2():e224. PubMed ID: 26556448
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
[No Abstract] [Full Text] [Related]
9. Malpositioning of a left atrial appendage occlusion device? A case with implications for percutaneous transcatheter left atrial appendage occlusion device therapy.
Schwartzman D; Katz WE; Smith AJ; Anderson WD
Heart Rhythm; 2007 May; 4(5):648-50. PubMed ID: 17467635
[No Abstract] [Full Text] [Related]
10. Closure of Left Atrial Appendage With Persistent Distal Thrombus Using an Amplatzer Amulet Occluder.
Lange M; Bültel H; Weglage H; Löffeld P; Wichter T
J Invasive Cardiol; 2016 Sep; 28(9):E75-6. PubMed ID: 27591691
[TBL] [Abstract][Full Text] [Related]
11. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials.
Catalá-López F; Corrales I; Martín-Serrano G; Tobías A; Calvo G
Med Clin (Barc); 2012 Oct; 139(10):421-9. PubMed ID: 22266082
[TBL] [Abstract][Full Text] [Related]
12. Successful Retrieval of a Dislodged Left Atrial Appendage Closure Device.
Lee OH; Lee H; Kim JS
JACC Cardiovasc Interv; 2017 Jan; 10(1):98-100. PubMed ID: 28057291
[No Abstract] [Full Text] [Related]
13. Asymptomatic dislocation of a Watchman left atrial appendage occluder.
Takayuki G; Grimmig O; Sören J; Dirk F
Asian Cardiovasc Thorac Ann; 2019 Jun; 27(5):394-395. PubMed ID: 30282462
[No Abstract] [Full Text] [Related]
14. Cardiac magnetic resonance for following-up device-related thrombosis after percutaneous left atrial appendage occlusion.
Obayashi Y; Kawai Miyake K; Shiomi H
Eur Heart J Cardiovasc Imaging; 2023 Feb; 24(3):e39. PubMed ID: 36512469
[No Abstract] [Full Text] [Related]
15. Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Au WY; Ma ES; Chow PC; Kan YT
Ann Hematol; 2014 May; 93(5):881-2. PubMed ID: 24048635
[No Abstract] [Full Text] [Related]
16. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
[No Abstract] [Full Text] [Related]
17. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
18. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
Depré F; Aboud N; Mayer B; Salama A
Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
[TBL] [Abstract][Full Text] [Related]
19. Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.
Mulla CM; Rashidi A; Levitov AB
Platelets; 2014; 25(2):144-6. PubMed ID: 23320857
[No Abstract] [Full Text] [Related]
20. Molecule of the month. Eltrombopag.
Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
[No Abstract] [Full Text] [Related]
[Next] [New Search]
